Drug pricing has been one of the central issues of the 2016 presidential campaign. There is currently a whirlwind of negative
public sentiment swirling around controversial pricing practices of companies like Valeant Pharmaceuticals Intl
Inc (NYSE: VRX), Mallinckrodt PLC
(NYSE: MNK) and Mylan NV (NASDAQ: MYL).
With the election only about a month away, there has probably never been a worse time for a drug company to raise prices. But as
the tweet below by @AndyBiotech shows, Ariad
Pharmaceuticals, Inc. (NASDAQ: ARIA) certainly
doesn’t seem to be deterred.
According to the tweet, Ariad has upped the price of its cancer drug Iclusig by 39 percent in 2016. While cancer patients are
paying more for Iclusig, Ariad’s share price has more than doubled in 2016, up 121.3 percent.
Democratic presidential nominee Hillary Clinton has been very clear about targeting drug companies that can’t justify their
price hikes.
“It’s wrong when drug companies put profits ahead of patients, raising prices without justifying the value behind them,” Clinton
said back in August.
Related Link: Drug Pricing Was
Not Even Mentioned At The First Presidential Debate
Surprisingly, the topic of drug pricing did not come up at the first presidential debate.
Mylan, Valeant and Mallinckrodt shares have all been hammered so far in 2016, down between 4.8 and 76.0 percent
year-to-date.
Full ratings
data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win
a $20 Amazon gift card!
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.